Vyome Holdings (NASDAQ: HIND) has announced the interim results from its investigator –initiated Phase 2 Proof of Concept study of VT-1953 topical gel in patients with malignant fungating wounds (MFW).
According to Vyome, the current results demonstrated encouraging signals of efficacy against symptoms of MFW in both investigator- and patient-reported outcomes.
In a statement, Dr. Sengupta, co-founder of Vyome, and associate professor of medicine at Harvard Medical School, commented, “Despite a large number of cancer patients suffering from the symptoms of MFW, there are no FDA-approved options for MFW. These early observations suggest VT-1953 is meeting the clinical benchmarks to advance further in clinical trials, and offer hope that a breakthrough treatment is potentially on the horizon for patients with MFW.”
Dr. Sengupta added, “I am excited to discuss our interim results further on Monday, September 8, 2025 (via live video conference) as well as our plan for upcoming milestones for this particular application.”
